Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Paracrine Signaling

Paracrine Signaling

Paracrine signaling allows cells to communicate with their immediate neighbors via secretion of signaling molecules. Such a signal can only trigger a response in nearby target cells because the signal molecules degrade quickly or are inactivated if not taken up. Prominent examples of paracrine signaling include nitric oxide signaling in blood vessels, synaptic signaling of neurons, the blood clotting system, tissue repair/wound healing, and local allergic skin reactions. Nitric oxide as a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Urea-based lysophosphatidic acid receptor 1 antagonists as potential migrastatics for triple-negative breast cancer.

Bioorganic chemistry·2026

Same author

The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.

British journal of pharmacology·2025

Same author

In memoriam: Morley D. Hollenberg (1944-2025), scientist, artist, mentor, and friend.

Canadian journal of physiology and pharmacology·2025

Same author

Defining the interactome of the pancreas-specific SPCA2 isoform (SPCA2C) identifies unique links to store-operated Ca<sup>2+</sup> entry.

The FEBS journal·2025

Same author

Lysophosphatidic Acid Receptor 1 (LPA<sub>1</sub>) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer.

ChemMedChem·2024

Same author

Transient receptor potential vanilloid 4 regulates extracellular matrix composition and mediates load-induced intervertebral disc degeneration in a mouse model.

Osteoarthritis and cartilage·2024

Search research articles

Related Experiment Video

Updated: May 21, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Developing PAR1 antagonists: minding the endothelial gap.

Rithwik Ramachandran¹

¹Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N4N1, Canada. rramacha@ucalgary.ca

Discovery Medicine

|June 30, 2012

Summary

This summary is machine-generated.

Proteinase Activated Receptors (PARs), a type of G-protein coupled receptor (GPCR), are activated by proteases. PAR1

More Related Videos

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption

Published on: October 4, 2019

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Related Experiment Videos

Last Updated: May 21, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption

Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption

Published on: October 4, 2019

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Area of Science:

Biochemistry and Molecular Biology
Pharmacology
Physiology

Background:

Proteinase Activated Receptors (PARs) are a unique class of G-protein coupled receptors (GPCRs) activated by proteolytic cleavage.
PARs play critical roles in various physiological and pathological processes.
PARs, particularly PAR1, are emerging as significant drug targets, especially for thrombosis.

Purpose of the Study:

To provide an overview of the Proteinase Activated Receptor family.
To focus on the role of PAR1 in regulating endothelial barrier integrity.
To discuss the implications of PAR1 function in developing PAR antagonists for anti-platelet therapy.

Main Methods:

Literature review of Proteinase Activated Receptors (PARs).
Analysis of PAR1's role in endothelial barrier function.
Examination of PAR antagonists in anti-platelet therapy development.

Main Results:

PARs are GPCRs activated by serine proteinases like thrombin.
PAR1 is implicated in maintaining endothelial barrier integrity.
PAR1 antagonists are under investigation for anti-platelet therapy.

Conclusions:

Understanding PARs, especially PAR1, is crucial for therapeutic advancements.
PAR1's role in endothelial barrier integrity offers potential for novel drug development.
PAR antagonists show promise as anti-platelet agents for conditions like thrombosis.